Incidence of acquired demyelination of the CNS in Canadian children

Banwell, Brenda; Kennedy, J. S.; Sadovnick, Dessa; Arnold, Douglas L.; Magalhaes, Sandra; Wambera, Katherine; Connolly, Mary; Yager, Jerome Y.; Mah, Jean K.; Shah, Naveed Nazir; Sébire, Guillaume; Meaney, Brandon; Dilenge, M-E; Lortie, Anne; Whiting, Sharon; Doja, Asif; Levin, Simon; Macdonald, Eilidh; Meek, David; Wood, Ellen; Lowry, Noel J.; Buckley, David; Yim, C.; Awuku, Mark; Guimond, Colleen; Cooper, Pamela; Grand’Maison, François; Baird, Janis; Bhan, Virender; Bar‐Or, Amit

doi:10.1212/01.wnl.0000339482.84392.bd

Cited by 322 publications

(243 citation statements)

References 20 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…Children with ADEM had the longest hospital stays, whereas children with ON had the shortest hospital stays ( Severe deficits in $1 feature of vision, motor, bladder and bowel function, or cognition were detected at ADS onset in 133 (47.0%) of 283 children, whereas 51 (18.0%) children had $1 moderate deficit, and 79 (27.9%) children had at least 1 mild deficit (Supplemental Fig 3A). Twenty (7.1%) children had a normal examination at study enrollment (days from onset, median [range]: 9 [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]); all had at least 1 deficit at onset verified according to records review of their presenting examination.…”

Section: Clinical Severitymentioning

confidence: 99%

Recovery From Central Nervous System Acute Demyelination in Children

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Clinical Severitymentioning

confidence: 99%

Recovery From Central Nervous System Acute Demyelination in Children

et al. 2015

View full text Add to dashboard Cite

show abstract

“…As the overall incidence of pediatric onset MS is low (0.18-0.51/100,000 per year) [4][5][6] enrolling an adequate number of patients for clinical trials will be challenging and will require multicenter international support. With patients enrolling from multiple centers, consensus definitions must be employed when diagnosing a patient with MS [7].…”

Section: Discussionmentioning

confidence: 99%

Clinical Trials in Pediatric Multiple Sclerosis: Pending Landscape and Challenges

Narula

Waldman²,

Banwell³

2014

Brain Disord The

View full text Add to dashboard Cite

Until recently, pediatric clinical trials were not required for new therapeutics. As a result, children were often prescribed medications off-label based on data from adult studies, or were unable to receive potentially beneficial therapies because of a lack of official approval for use in the pediatric population. As this was deemed unethical and detrimental in some cases, legislation was recently approved that now mandates pediatric studies for all new therapeutics.Implementation of clinical trials in pediatric MS is especially germane as there are a number of emerging oral and intravenous therapies that may be more tolerable and effective than the platform injectable therapies. As pediatric MS trials are now being designed, challenges regarding their feasibility have been identified. These include sample size limitations, determination of appropriate study endpoints and pediatric MS-specific outcomes, and fear about the unknown impact of these new agents on the maturing immune, reproductive, and central nervous system. In this commentary, we discuss the pending landscape of pediatric MS trials and their anticipated challenges.

show abstract

“…Three population-based studies attempted to estimate the incidence of pediatric ATM. The Canadian Paediatric Surveillance Program estimated the incidence of ATM to be 0.2 per 100 000 children (Banwell et al, 2009). This survey found that ATM affected girls about as often as boys (0.81:1) and found no seasonal variation or peak age at symptom onset.…”

Section: Pediatric Acute Transverse Myelitismentioning

confidence: 99%